Mea culpa. I just went back and re-read both the 3Q and 4Q Press releases -- 29 pages. I could not find that information I posted. Either I misread or the CC indicated more than I read. The continued buy back of common doesn't hurt, Core earnings for 4Q 2013 $.31 plus drop income $0.07 or $.38/share is a good indicator. GAAP 4Q losses could hurt, so the jury is out. Thank you for your comment.
I'm completely out of OPTR, and did well with trades to counteract the "Pro" who also did well on the short side. If it goes to ~$12, I'll buy. Maybe even up to $12.44. HOWEVER, there are other stocks or funds that carry less baggage.
Oh my. Pro you say a lot of things -- but I just want you to tell me how you covered at $7, which was where you insisted it was going. Oops. I love that you are such a comedian. Keep it up. Pro boy.
That is quite a resume for Steve Haslam! COO, CEO, CEO. The results at Streetlinks speak well of him, to say the least. Watch him repeat the feat with CorvisaCloud.
I should have noted this is a SCHEDULE 13G (Rule 13d-102)
Comprised of an aggregate of 2,697,659 shares of common stock held by Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., of which Deerfield Management Company, L.P. is the investment advisor.
and... AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON... 1,516,086 shares OPTR James E Flynn
Oh, man, I wish I had been in town this week, Pro. Good job for you and your buddies making OPTR shares available at SWEET prices. To top that Yahoo joined in your "thingy" and this message board is out of order. Has that been since 5/13??? So, this time I hope you covered your fine bottom, along with your cohorts. Just now, I find a sweet end to a sweet week. Oh my. See you around, but probably not here. Have any other monikers? Salud.
Yikes, you are still lurking here, pro! Are you still short? What is your target for going short again, or did you stay short since it didn't reach that $7 price.
I've recharacterized some NOVC shares from an IRA into a ROTH. :)) Thanks to the bashers who have managed to keep the price in check for my taxes.
I could live with that... :) Still, IMO we will first see an offer -- the first step of the dance. Then the analysts will join the discussion, and proinvester will be gone forevermore. IMO, he is now long and will soon re-emerge as "profitter". Or not. Gosh, I miss him.
Pharmaceuticals Inc. (OPTR), the antibiotics maker that’s weighing a sale, drew interest from drugmakers including GlaxoSmithKline Plc (GSK) and Japan’s Astellas Pharma Inc. (4503), said two people familiar with the matter. The shares surged.
The maker of the antibiotic Dificid aims to fetch as much as $1 billion in a possible auction, said the people, who asked not to be named because the process is private. Optimer also attracted interest from Cubist Pharmaceuticals Inc. (CBST) and AstraZeneca Plc, said one of the people.
Buying Optimer would allow the drugmakers to generate more revenue from hospitals, as Dificid, the company’s sole drug on the market, treats a bacterium linked to intestinal infections in hospitalized patients. The drugmaker also may prove attractive to peers that already distribute to medical facilities, because they could use existing distribution channels to reduce costs.
Optimer shares climbed as much as 24 percent following Bloomberg’s report. They advanced to $14.48 at 9:37 a.m. in New York, giving the company a market value of almost $700 million.
Optimer said on Feb. 27 that the board would examine “a full range” of strategic alternatives. The company is working with Centerview Partners LLC and JPMorgan Chase & #$%$ the process.
Former Chairman Michael Chang left Optimer last year after the board found that he failed to identify and manage conflict of interest issues tied to a stock grant. The company also replaced Chief Executive Officer Pedro Lichtinger in February, when Optimer disclosed the board’s strategic review.
Representatives for JPMorgan, Astellas, Glaxo, Cubist and AstraZeneca declined to comment. Optimer spokesman David Walsey didn’t return calls seeking comment.
Hi Ucited. I didn't see any new press release from OPTR, so I expect it was an analyst making his projections and listing those previously suspected to be candidates. I welcome their suggestions, but I would welcome more a bid and competition for buying OPTR.